GSK seeks advice on planned Scottish respiratory API plant

By Gareth Macdonald

- Last updated on GMT

GSK plant in Montrose (source GSK)
GSK plant in Montrose (source GSK)

Related tags Pharmacology United kingdom Pharmaceutical drug

GSK has asked Angus Council for advice as it prepares to submit a planning application for an API plant it intends to build at its site in Montrose, Scotland.

The UK pharmaceutical manufacturer confirmed it has sought guidance from the council’s planning department this week, telling us “we are at the scoping stage ahead of a full planning application​.”

Reports​ in the UK press suggest the new facility will produce salbutamol, the API in GSK's asthma treatment Ventolin.

The Montrose facility has been making drug ingredients for six decades. In 2003, GSK almost sold the facility to Akzo Nobel.

However, that deal fell through and GSK changed its plan a few years later​ after failing to find a replacement buyer.

At present the facility produces active ingredients for respiratory, HIV and vaccine products and employs over 450 staff.

Expansion plan

The firm first mooted the idea of building a new active pharmaceutical ingredient (API) facility at the site in July when it said it would spend £110m ($136m) on a manufacturing plant for respiratory active ingredients.

At the time GSK said: “A number of jobs will be created during the estimated three year construction phase.

Once on-line, the new state-of-the-art facility will provide long term security for the existing manufacturing related roles and will ensure a continued supply of respiratory medicine to millions of patients around the world​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more